VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib

British Journal of Cancer

Volumn 108, Issue 5, 2013, Pages 1126-1132

  Scartozzi, M ^a   Bianconi, M ^a   Faloppi, L ^a   Loretelli, C ^a   Bittoni, A ^a   Del Prete, M ^a   Giampieri, R ^a   MacCaroni, E ^a   Nicoletti, S ^a   Burattini, L ^a   Minardi, D ^b   Muzzonigro, G ^b   Montironi, R ^a   Cascinu, S ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

angiogenesis; polymorphism; renal cell carcinoma; sunitinib; VEGF

Indexed keywords

SUNITINIB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRROLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84875464258     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.501     Document Type: Article

References (38)

1. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, Inoue I, Katayama S (2002) A common polymorphism in the 50-untranslatedregion of the VEGF gene is associated with diabetic retinopathy in type 2diabetes. Diabetes 51: 1635-1639.
2. Chen MH, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, Jiang JK, WangHS, Wang WS (2011) VEGF-406 T-polymorphism and its associationwith VEGF expression and outcome to FOLFOX-4 treatment in patientswith colorectal carcinoma. Pharmacogenomics J 11 (3) : 227-236.
3. Debette S, Visvikis-Siest S, Chen MH, Ndiaye NC, Song C, Destefano A, SafaR, Azimi Nezhad M, Sawyer D, Marteau JB, Xanthakis V, Siest G, SullivanL, Pfister M, Smith H, Choi SH, Lamont J, Lind L, Yang Q, Fitzgerald P, Ingelsson E, Vasan RS, Seshadri S (2011) Identification of cis-and transactinggenetic variants explaining up to half the variation in circulatingvascular endothelial growth factor levels. Circ Res 109 (5) : 554-563.
4. Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, MichaelsonMD, Motzer RJ (2007) Circulating protein biomarkers ofpharmacodynamic activity of sunitinib in patients with metastatic renalcell carcinoma: modulation of VEGF and VEGF-related proteins. J TranslMed 5: 32-43.
5. Ferrante M, Pierik M, Henckaerts L, Joossens M, Claes K, Van Schuerbeek N, Vlietinck R, Rutgeerts P, Van Assche G, Vermeire S (2006) The role ofvascular endothelial growth factor (VEGF) in inflammatory bowel disease.Inflamm Bowel Dis 12: 870-878.
6. Formento JL, Etienne-Grimaldi MC, Francoual M, Pagès G, Onesto C, Formento P, Chamorey E, Dassonville O, Poissonnet G, Milano G (2009) Influence of the VEGF-A 936C4T germinal polymorphism on tumoralVEGF expression in head and neck cancer. Pharmacogenomics 10:1277-1283.
7. Garcia-Donas J, Esteban E, Leandro-Garća LJ, Castellano DE, del Alba AG, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Mellado B, Mart́nez E, Moreno F, Font A, Robledo M, Rodŕguez-Antona C (2011) Single nucleotide polymorphism associations with response and toxiceffects in patients with advanced renal-cell carcinoma treated with firstlinesunitinib: a multicentre, observational, prospective study. LancetOncol 12 (12) : 1143-1150.
8. Gunningham SP, Currie MJ, Han C, Turner K, Scott PA, Robinson BA, HarrisAL, Fox SB (2001) Vascular endothelial growth factor-B and vascularendothelial growth factor-C expression in renal cell carcinomas: regulationby the von Hippel-Lindau gene and hypoxia. Cancer Res 61: 3206-3211.
9. Hansen TF, Garm Spindler KL, Andersen RF, Lindebjerg J, Brandslund I, Jakobsen A (2011) The predictive value of genetic variations in thevascular endothelial growth factor gene A in metastatic colorectal cancer. Pharmacogenomics J 11: 53-60.
10. Hansen TF, Sørensen FB, Spindler KL, Olsen DA, Andersen RF, Lindebjerg J, Brandslund I, Jakobsen A (2010) Microvessel density and the associationwith single nucleotide polymorphisms of the vascular endothelial growthfactor receptor 2 in patients with colorectal cancer. Virchows Arch 456:251-260.
11. Jain RK (2005) Normalization of tumor vasculature: an emerging concept inantiangiogenic therapy. Science 307: 58-62.
12. Jia H, Bagherzadeh A, Bicknell R, Duchen MR, Liu D, Zachary I (2004) Vascular endothelial growth factor (VEGF)-D and VEGF-A differentiallyregulate KDR-mediated signaling and biological function in vascularendothelial cells. J Biol Chem 279: 36148-36157.
13. Kamoun M, Houman MH, Hamzaoui A, Hamzaoui K (2008) Vascularendothelial growth factor gene polymorphisms and serum levels inBehcet's disease. Tissue Antigen 72: 581-587.
14. Kim JJ, Vaziri SAJ, Rini BI, Elson P, Garcia JA, Wirka R, Dreicer R, GanapathiMK, Ganapathi R (2012) Association of VEGF and VEGFR2 singlenucleotide polymorphisms with hypertension and clinical outcome inmetastatic clear cell renal cell carcinoma patients treated with sunitinib.Cancer 118 (7) : 1946-1954.
15. Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, MaltezosE, Sivridis E (2004) VEGF gene sequence variation defines VEGF geneexpression status and angiogenic activity in non-small cell lung cancer.Lung Cancer 46: 293-298.
16. Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, WascherTC, Paulweber B, Haas J, Sammonigg H (2003) A common 936 C/T genepolymorphism of vascular endothelial growth factor is associated withdecreased breast cancer risk. Int J Cancer 106: 468-471.
17. Laakkonen P, Waltari M, Holopainen T, Takahashi T, Pytowski B, Steiner P, Hicklin D, Persaud K, Tonra JR, Witte L, Alitalo K (2007) Vascularendothelial growth factor receptor 3 is involved in tumor angiogenesis andgrowth. Cancer Res 67: 593-599.
18. Lam JS, Lepert JT, Belldegrun AS, Figlin RA (2005) Novel approachesin the therapy of metastatic renal cell carcinoma. World J Urol 23: 202-212.
19. Minchenko A, Salceda S, Bauer T, Caro T (1994) Hypoxia regulatory elementsof the human vascular endothelial growth factor gene. Cell Mol Biol Res40: 35-39.
20. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results forsunitinib compared with interferon alfa in patients with metastatic renalcell carcinoma. J Clin Oncol 27: 3584-3590.
21. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cellcarcinoma. N Engl J Med 356: 115-124.
22. Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, LoehrerP, Wilding G, Fairclough DL, Cella D, Mazumdar M (2000) Phase III trialof interferon alfa-2a with or without 13-cis-retinoic acid for patients withadvanced renal cell carcinoma. J Clin Oncol 18: 2972-2980.
23. Pages G, Puyssegur J (2005) Transcriptional regulation of the vascularendothelial growth factor gene-a concert of activating factors. CardiovascRes 65: 564-573.
24. Pander J, Gelderblom H, Guchelaar HJ (2007) Pharmacogenetics of EGFR andVEGF inhibition. Drug Discov Today 12: 1054-1060.
25. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA (2003) Pathobiology, prognosisand targeted therapy for renal cell carcinoma: exploiting the hypoxiainducedpathway. Clin Cancer Res 9: 4641-4652.
26. Petrovic MG, Korosec P, Kosnik M, Osredkar J, Hawlina M, Peterlin B, Petrovic D (2008) Local and genetic determinants of vascular endothelialgrowth factor expression in advanced proliferative diabetic retinopathy.Mol Vis 14: 1382-1387.
27. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E (2000) Acommon 936 C/T mutation in the gene for vascular endothelial growthfactor is associated with vascular endothelial growth factor plasma levels. JVasc Res 37: 443-448.
28. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, StadlerWM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ (2008) Antitumor activity and biomarker analysis of sunitinibin patients with bevacizumab refractory metastatic renal cell carcinoma. JClin Oncol 26: 3743-3748.
29. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, FlockhartDA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD (2008) Association of vascularendothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in trial of paclitaxel comparedwith paclitaxel compared with paclitaxel plus bevacizumab in advancedbreast cancer: ECOG 2100. J Clin Oncol 20: 4672-4678.
30. Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia AA, MorganR, Gandara D, Scudder S, Oza A, Hirte H, Fleming G, Roman L, Lenz HJ (2008) Polymorphisms and clinical outcome in recurrent ovarian cancertreated with cyclophosphamide and bevacizumab. Clin Cancer Res 14:7554-7563.
31. Schultz A, Lavie L, Hochberg I, Beyar R, Stone T, Skorecki K, Lavie P, RoguinA, Levy AP, Steffensen KD, Waldstrom M, Brandslund I, Jakobsen A (1999) Interindividual heterogeneity in the hypoxic regulation of VEGF:significance for the development of the coronary artery collateralcirculation. Circulation 100: 547-552.
32. Steffensen KD, Waldstrom M, Brandslund I, Jakobsen A (2010) Therelationship of VEGF polymorphisms with serum VEGF levels andprogression-free survival in patients with epithelial ovarian cancer.Gynecol Oncol 117: 109-116.
33. Stuttfeld E, Ballmer-Hofer K (2009) Structure and function of VEGFreceptors. IUBMB Life 61 (9) : 915-922.
34. Valtola R, Salven P, Heikkila P, Taipale J, Joensuu H, Rehn M, Pihlajaniemi T, Weich H, de Waal R, Alitalo K (1999) VEGFR-3 and its ligandVEGF-C are associated with angiogenesis in breast cancer. Am J Pathol154: 1381-1390.
35. Vaziri SAJ, Kim J, Ganapathi MK, Ganapathi R (2010) Vascular endothelialgrowth factor polymorphisms: role in response and toxicity of tyrosinekinase inhibitors. Curr Oncol Rep 12: 102-108.
36. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE (2000) Identification ofpolymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12:1232-1235.
37. Zhai R, Gong MN, Zhou W, Thompson TB, Kraft P, Su L, Christiani DC (2007) Genotypes and haplotypes of the VEGF gene are associated withhigher mortality and lower VEGF plasma levels in patients with ARDS.Thorax 62: 718-722.
38. Zhang F, Tang Z, Hou X, Lennartsson J, Li Y, Koch AW, Scotney P, Lee C, Arjunan P, Dong L, Kumar A, Rissanen TT, Wang B, Nagai N, Fons P, Fariss R, Zhang Y, Wawrousek E, Tansey G, Raber J, Fong GH, Ding H, Greenberg DA, Becker KG, Herbert JM, Nash A, Yla-Herttuala S, Cao Y, Watts RJ, Li X (2009) VEGF-B is dispensable for blood vessel growth butcritical for their survival, and VEGF-B targeting inhibits pathologicalangiogenesis. Proc Natl Acad Sci USA 106: 6152-6157.